BJP takes swipe at Cong over Covaxin efficacy, says must be proud of result

A day after Bharat Biotech said its anti-coronavirus vaccine has shown 81 per cent efficacy, the BJP on Thursday hit out at the Congress

Covaxin
Covaxin | File photo
Press Trust of India New Delhi
2 min read Last Updated : Mar 04 2021 | 7:57 PM IST

A day after Bharat Biotech said its anti-coronavirus vaccine has shown 81 per cent efficacy, the BJP on Thursday hit out at the Congress for questioning the drug regulator's decision to grant it emergency use approval and said everyone should be proud of the results shown by it.

Taking a jibe at the Congress, BJP spokesperson Gaurav Bhatia claimed the Gandhi family would have been the first to get a vaccine if the Congress party was in power.

The Narendra Modi government ended the VIP culture and ensured that healthcare and frontline workers will be the first to get the jab, he said.

Bhatia said no one will forget how senior Congress leaders such as Shashi Tharoor and Jairam Ramesh had questioned the indigenously developed vaccine Covaxin.

After the drugs regulator approved Covaxin for restricted emergency use in the country in January, some senior Congress leaders had criticised the move noting that it was given the nod without phase three trial data.

The Congress government in Chhattisgarh even demanded that Covaxin should not be sent to the state, Bhatia noted and then lauded opposition leaders like Sharad Pawar and Naveen Patnaik for taking Covid vaccine and not doing politics over the issue.

"They gave the message that there should be no politics over some issues," he said.

Bharat Biotech's Covaxin vaccine, whose emergency use approval before finishing final stage testing had triggered a row, has shown an 81 per cent efficacy in preventing symptomatic COVID-19 disease in an interim analysis of the advanced clinical trial, the company said on Wednesday, boosting prospects of its usage.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Bharatiya Janata PartyIndian National CongressCoronavirus Vaccine

First Published: Mar 04 2021 | 7:53 PM IST

Next Story